New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia

Deborah A. Thomas, Susan O'Brien, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalReview article

Abstract

The discovery of targeted ABL tyrosine kinase inhibitors has allowed significant advances in the treatment of de novo Philadelphia chromosome (Ph)-positive ALL. Whereas the outcome with standard chemotherapy was previously dismal, the use of imatinib in front-line therapy has improved relapse-free survival and overall survival, even in the absence of allogeneic stem cell transplantation in first complete remission (particularly for those with comorbidities or lack of a suitable donor). However, the emergence of resistance to imatinib presents a new therapeutic, challenge. Novel tyrosine kinase inhibitors with enhanced inhibitory potency against ABL and other kinases may further improve on the results observed with imatinib. Optimal use of these novel agents in the treatment schema of Ph-positive ALL will be paramount in ensuring continued success in the eradication of this disease.

Original languageEnglish (US)
Pages (from-to)183-189
Number of pages7
JournalCurrent Hematologic Malignancy Reports
Volume2
Issue number3
DOIs
StatePublished - Jul 1 2007
Externally publishedYes

Fingerprint

Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein-Tyrosine Kinases
Disease Eradication
Stem Cell Transplantation
Therapeutics
Comorbidity
Phosphotransferases
Recurrence
Drug Therapy
Imatinib Mesylate

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia. / Thomas, Deborah A.; O'Brien, Susan; Cortes, Jorge; Kantarjian, Hagop.

In: Current Hematologic Malignancy Reports, Vol. 2, No. 3, 01.07.2007, p. 183-189.

Research output: Contribution to journalReview article

Thomas, Deborah A. ; O'Brien, Susan ; Cortes, Jorge ; Kantarjian, Hagop. / New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia. In: Current Hematologic Malignancy Reports. 2007 ; Vol. 2, No. 3. pp. 183-189.
@article{d82fe9cae42d4d02b88fe6ebb5754f22,
title = "New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia",
abstract = "The discovery of targeted ABL tyrosine kinase inhibitors has allowed significant advances in the treatment of de novo Philadelphia chromosome (Ph)-positive ALL. Whereas the outcome with standard chemotherapy was previously dismal, the use of imatinib in front-line therapy has improved relapse-free survival and overall survival, even in the absence of allogeneic stem cell transplantation in first complete remission (particularly for those with comorbidities or lack of a suitable donor). However, the emergence of resistance to imatinib presents a new therapeutic, challenge. Novel tyrosine kinase inhibitors with enhanced inhibitory potency against ABL and other kinases may further improve on the results observed with imatinib. Optimal use of these novel agents in the treatment schema of Ph-positive ALL will be paramount in ensuring continued success in the eradication of this disease.",
author = "Thomas, {Deborah A.} and Susan O'Brien and Jorge Cortes and Hagop Kantarjian",
year = "2007",
month = "7",
day = "1",
doi = "10.1007/s11899-007-0025-z",
language = "English (US)",
volume = "2",
pages = "183--189",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - New approaches to the management of Philadelphia chromosome-positive acute lymphocytic leukemia

AU - Thomas, Deborah A.

AU - O'Brien, Susan

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2007/7/1

Y1 - 2007/7/1

N2 - The discovery of targeted ABL tyrosine kinase inhibitors has allowed significant advances in the treatment of de novo Philadelphia chromosome (Ph)-positive ALL. Whereas the outcome with standard chemotherapy was previously dismal, the use of imatinib in front-line therapy has improved relapse-free survival and overall survival, even in the absence of allogeneic stem cell transplantation in first complete remission (particularly for those with comorbidities or lack of a suitable donor). However, the emergence of resistance to imatinib presents a new therapeutic, challenge. Novel tyrosine kinase inhibitors with enhanced inhibitory potency against ABL and other kinases may further improve on the results observed with imatinib. Optimal use of these novel agents in the treatment schema of Ph-positive ALL will be paramount in ensuring continued success in the eradication of this disease.

AB - The discovery of targeted ABL tyrosine kinase inhibitors has allowed significant advances in the treatment of de novo Philadelphia chromosome (Ph)-positive ALL. Whereas the outcome with standard chemotherapy was previously dismal, the use of imatinib in front-line therapy has improved relapse-free survival and overall survival, even in the absence of allogeneic stem cell transplantation in first complete remission (particularly for those with comorbidities or lack of a suitable donor). However, the emergence of resistance to imatinib presents a new therapeutic, challenge. Novel tyrosine kinase inhibitors with enhanced inhibitory potency against ABL and other kinases may further improve on the results observed with imatinib. Optimal use of these novel agents in the treatment schema of Ph-positive ALL will be paramount in ensuring continued success in the eradication of this disease.

UR - http://www.scopus.com/inward/record.url?scp=34547791944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547791944&partnerID=8YFLogxK

U2 - 10.1007/s11899-007-0025-z

DO - 10.1007/s11899-007-0025-z

M3 - Review article

C2 - 20425368

AN - SCOPUS:34547791944

VL - 2

SP - 183

EP - 189

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 3

ER -